Blueprint Medicines CORP Form 4 insider transactions
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, sold 2,436 shares of common stock on June 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Chief Medical Officer of Blueprint Medicines, L. Becker Hewes, exercised stock options and sold shares of common stock on May 31, 2024, and June 3, 2024, according to a Form 4 filing with the SEC.
Ariel Hurley, Principal Accounting Officer at Blueprint Medicines, executed stock options and sold shares on May 15, 2024, according to a Form 4 filing with the SEC.
Michael Landsittel, CFO of Blueprint Medicines, sold a portion of his company shares on May 15, 2024, under a pre-arranged trading plan.
Michael Landsittel, CFO of Blueprint Medicines, exercised stock options on May 8, 2024, acquiring shares at prices of $1.87 and $8.8.
Form 4: Blueprint Medicines CFO Michael Landsittel Executes Stock Option and Sells Shares Under 10b5-1 Plan
Michael Landsittel, CFO of Blueprint Medicines, exercised stock options and sold 10,000 shares of common stock at $105 per share on May 2, 2024, under a pre-arranged trading plan.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reports exercising stock options and selling shares under a pre-arranged trading plan.
Form 4: Blueprint Medicines CFO Michael Landsittel Executes Stock Option and Sells Shares Under 10b5-1 Plan
Michael Landsittel, CFO of Blueprint Medicines, exercised stock options and sold 5,000 shares of common stock at \$95 per share on March 28, 2024, under a pre-arranged trading plan.
Jeffrey W. Albers, a director at Blueprint Medicines Corp, sold 11,033 shares of common stock on March 7, 2024, to cover tax withholding obligations.
Form 4: Blueprint Medicines Director Albers Executes Stock Options and Sells Shares Under 10b5-1 Plan
Jeffrey Albers, a director at Blueprint Medicines, exercised stock options and sold shares of common stock on March 20, 2024, according to a Form 4 filing with the SEC.
Form 4: Blueprint Medicines CFO Michael Landsittel Executes Stock Option and Sells Shares Under 10b5-1 Plan
Michael Landsittel, CFO of Blueprint Medicines, exercised stock options and sold shares of common stock on March 15, 2024, under a pre-arranged trading plan.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, exercised stock options and sold shares on March 15, 2024, according to a Form 4 filing.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, reports the acquisition and disposal of company stock on March 13, 2024.
Hewes L. Becker, Chief Medical Officer of Blueprint Medicines Corp, sold 3,097 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Kate Haviland, CEO of Blueprint Medicines, sold 12,464 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, sold 2,934 shares of common stock at $90.69 to cover tax withholding obligations related to vesting restricted stock units.
Christopher K. Murray, Chief Technical Operations Officer of Blueprint Medicines Corp, sold 2,521 shares of common stock to cover tax withholding obligations.
Michael Landsittel, CFO of Blueprint Medicines Corp, sold 5,003 shares of common stock on March 7, 2024, at a price of $90.69 to cover tax withholding obligations.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold 6,070 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Fouad Namouni, President of R&D at Blueprint Medicines, sold 4,377 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, sold 2,286 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Tracey McCain, EVP and Chief Legal Officer of Blueprint Medicines Corp, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, sold 1,462 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Tracey McCain, EVP and Chief Legal Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, reports the acquisition of restricted stock units and stock options.
Form 4: Blueprint Medicines Executive Fouad Namouni Receives Stock Options and Restricted Stock Units
Fouad Namouni, President of R&D at Blueprint Medicines, was granted 15,000 restricted stock units and options to purchase 30,000 shares of common stock on March 1, 2024.
Debra Durso-Bumpus, Chief People Officer at Blueprint Medicines, was granted stock options and restricted stock units on March 1, 2024.
Christina Rossi, Chief Operating Officer of Blueprint Medicines, reports the acquisition of 15,000 restricted stock units and an option to purchase 30,000 shares of common stock.
Hewes L. Becker, Chief Medical Officer of Blueprint Medicines, received stock options and restricted stock units on March 1, 2024, according to a recent SEC filing.